NEWS
Paul Hastings Advises Barclays, BTIG and Titan Partners on Humacyte’s Public Offering
June 15, 2026
Paul Hastings LLP advised Barclays, BTIG and Titan Partners as joint bookrunning managers for Humacyte Inc.’s (Nasdaq: HUMA) $50 million public offering of 47,619,048 shares of its common stock at a price of $1.05 per share. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering closed on June 12, 2026.
Equity Capital Markets and Corporate Life Sciences chair Seo Salimi and partner Will Magioncalda led the Paul Hastings team, which also included associate Katie Warshauer.
More details can be found here.
About Paul Hastings
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.